L. J. SANDLOW, M.D.; H. A. ALLEN, M.D.; H. NECHELES, M.D., PH.D., F.A.C.P.
The introduction of fluorescent techniques in the study of tissue has provided new approaches for detecting cancer.
Rall, Loo, Lane, and Kelly (1) studied a patient with metastatic breast carcinoma who had been treated with a fluorescent riboflavin antagonist, U 6538. At autopsy, a yellow fluorescence in the tumor was noted, which persisted for days, although fluorescence of U 6538 was found to last only for a few hours. Tumors that had fluoresced were studied in other patients who had not received this drug. By a process of elimination it was found that these patients had received tetracycline.
Learn more about subscription options.
Register Now for a free account.
SANDLOW LJ, ALLEN HA, NECHELES H. The Use of Tetracycline Fluorescence in the Detection of Gastric Malignancy. Ann Intern Med. 1963;58:409–413. doi: 10.7326/0003-4819-58-3-409
Download citation file:
Published: Ann Intern Med. 1963;58(3):409-413.
Gastric Cancer, Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only